EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Targeting SPP1 + TAMs associated with liver metastasis reverses immunosuppression and synergizes with immunotherapy in colorectal cancer

Yilin Lin, Zhihua Chen, Shidong Zhao, Long Zhao, Changjiang Yang, Mingxuan Zhu, Yingjiang Ye, Shan Wang, Zhanlong Shen

Journal for ImmunoTherapy of Cancer · 2026

DOI: 10.1136/jitc-2025-014128 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2026. Verfasst von Yilin Lin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterological Surgery, Peking University People's Hospital, Beijing, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Liver Neoplasms, Immunotherapy, Tumor-Associated Macrophages. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Beijing Bethune Charitable Foundation, National Key Research and Development Program of China Stem Cell and Translational Research, the Beijing Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tumor-associated macrophages (TAMs) are critically involved in colorectal cancer (CRC) progression, yet their spatial and metabolic heterogeneity across primary and metastatic microenvironments remains poorly defined, limiting therapeutic development.

Methods

Integrated single-cell RNA sequencing was performed on 998,204 cells from a multicenter cohort encompassing primary CRC, adjacent normal tissue, liver and lymph node metastases, and peripheral blood. Computational analyses included uniform manifold approximation and projection (UMAP) clustering, pseudotime inference, RNA velocity, and CellChat. Findings were validated using multiplex immunohistochemistry, spatial transcriptomics, and in vivo preclinical models.

Results

This study identified two distinct TAM populations: SPP1 + and SEPP1 + TAMs. SPP1 + TAMs, associated with angiogenesis, immune evasion, and liver metastasis, were linked to poorer prognosis. This population exhibited tissue-specific differentiation trajectories and comprised two metabolic subtypes: a glycolytic ATP5F1E + subtype enriched in primary tumors and lymph nodes, and an oxidative phosphorylation-dominant MT-CO1 + subtype specific to liver metastases. Spatially, MT-CO1 + SPP1 + TAMs localized to oxygen-rich invasive margins, while ATP5F1E + SPP1 + TAMs resided in hypoxic tumor cores. Functionally, SPP1 + TAMs drove CD8 + T-cell exhaustion and spatial exclusion. In preclinical models, combined regorafenib and anti-programmed cell death protein 1 therapy reduced SPP1 + TAM infiltration and suppressed tumor growth and metastasis.

Conclusion

This study delineates the spatial, developmental, and metabolic heterogeneity of SPP1 + TAMs in CRC, identifying SPP1 + TAMs as key mediators of immunosuppression and metastasis. Targeting these populations with combination therapy effectively enhances antitumor immunity, presenting a novel translational strategy for CRC immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsLiver NeoplasmsImmunotherapyTumor-Associated MacrophagesHumansAnimalsMiceFemaleTumor Microenvironment

Stichwörter der Autor:innen

Colorectal CancerImmunotherapyMacrophage

Autor:innen und Institutionen

  • Department of Gastroenterological Surgery, Peking University People's Hospital, Beijing, China.
  • Department of Thoracic Surgery, the First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian, China.
  • Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, China.
  • Peking University People's Hospital, Beijing, China.
  • Beijing Key Laboratory of Precision Diagnosis, Treatment and Translational Research for Colorectal Cancer, Peking University People's Hospital, Beijing, China.
  • Department of Gastroenterological Surgery, Peking University People's Hospital, Beijing, China shenzhanlong@pkuph.edu.cn.

Förderung

  • Beijing Bethune Charitable Foundation
  • National Key Research and Development Program of China Stem Cell and Translational Research
  • the Beijing Natural Science Foundation
  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Beijing Advanced Center of Cellular Homeostasis and Aging-Related Diseases
  • Beijing Xisike Clinical Oncology Research Foundation

Zitieren

APA

Lin, Y., Chen, Z., Zhao, S., Zhao, L., Yang, C., Zhu, M., Ye, Y., Wang, S., & Shen, Z. (2026). Targeting SPP1 + TAMs associated with liver metastasis reverses immunosuppression and synergizes with immunotherapy in colorectal cancer. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-014128

Vancouver

Lin Y, Chen Z, Zhao S, Zhao L, Yang C, Zhu M, et al. Targeting SPP1 + TAMs associated with liver metastasis reverses immunosuppression and synergizes with immunotherapy in colorectal cancer. Journal for ImmunoTherapy of Cancer. 2026. doi:10.1136/jitc-2025-014128

BibTeX
@article{Lin2026,
  author = {Lin, Yilin and Chen, Zhihua and Zhao, Shidong and Zhao, Long and Yang, Changjiang and Zhu, Mingxuan and Ye, Yingjiang and Wang, Shan and Shen, Zhanlong},
  title = {Targeting SPP1 + TAMs associated with liver metastasis reverses immunosuppression and synergizes with immunotherapy in colorectal cancer},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  doi = {10.1136/jitc-2025-014128}
}
Kostenlos starten →